Clearly defined amplification curves were observed for the two positive recombinant plasmids in their predicted fluorescence channels.
Using ⩾5 copies of h TERT gene copy per nucleus in at least 20% of the cells to define amplification, Zhang et al (2000) reported h TERT amplification in 38% (eight out of 21) of lung carcinomas.
A fundamental approach to analyzing the kinetics of PCR amplification is based upon defining amplification efficiency as the relative increase in amplicon DNA over a single cycle: (5) E C = F C F C − 1 − 1 where F C -1 is the reaction fluorescence of the preceding cycle.
Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC).
Amplification per allele (Amp/A) was defined as amplification of individual alleles in a locus, and was calculated in heterozygous and hemizygous loci, but not in homozygous loci, where it is not possible to distinguish between amplification of one allele from amplification of both alleles (note that in hemizygous loci, Amp/L and Amp/A necessarily have equal values).
Using qPCR that defines amplification as tumours with h TERT gene content greater than that of PIK3R1 (5q13.1), we found amplification in 57% of NSCLC.
Here, this phenomenon is defined as amplification and carrying in the series-connected valveless piezoelectric pump with cone-shaped tubes.
HER2 amplification defined by MLPA in the present study strongly correlated with HER2 amplification status defined by CISH on TMA slides.
For each stage, protein family, and intron, Table 1 and Table 2 report the results of the PCR for each genus as observed on agarose gels (Fig. 4) (and the total number of genera), distinguishing the three quality levels 'P'(Promising), 'I' (Intron-size amplicon) and 'A' (Amplification) defined in the Methods section V.
In previous studies, centrosome amplification, defined as an increase in the centrosome number, has been identified in many different tumors, including bladder cancer [ 15, 16].
The Allred scoring system was employed and tumours were considered positive when the score was ≥ 3. HER2 gene amplification was defined based on chromogenic in situ hybridisation analysis using a US Food and Drug Administrator approved probe (SpotLight HER2 amplification probe, Invitrogen, Carlsbad, CA, USA) and/or by inspection of the results of aCGH analysis, as previously described [ 20].
